Clinical trial
Dose Climbing Trial of Anlotinib Plus Gefitinib in the First-line Treatment of Advanced Gene Positive Non-squamous Non-small Cell Lung Cancer
NCT03602027 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Nanchang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dose Climbing Trial of Anlotinib Plus Gefitinib in the First-line Treatment of Advanced Gene Positive Non-squamous Non-small Cell Lung Cancer
- Lead sponsor
- Second Affiliated Hospital of Nanchang University
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- August 1, 2018
- Completion date
- February 1, 2019
- Enrollment
- 9 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
non-squamous non-small cell lung cancer